Pacira BioSciences downgraded by Raymond James
$PCRX
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James downgraded Pacira BioSciences from Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $27.00 | Equal Weight | Barclays |
| 11/17/2025 | Buy | H.C. Wainwright | |
| 7/25/2025 | $30.00 | Hold → Buy | Truist |
| 1/30/2025 | $8.00 → $25.00 | Sell → Hold | Truist |
| 8/13/2024 | $30.00 → $8.00 | Buy → Sell | Truist |
| 8/12/2024 | $42.00 → $11.00 | Overweight → Neutral | Piper Sandler |
| 8/12/2024 | $45.00 → $10.00 | Overweight → Underweight | JP Morgan |
| 8/12/2024 | Outperform → Mkt Perform | Raymond James |
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
144 - Pacira BioSciences, Inc. (0001396814) (Subject)
SCHEDULE 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-actin
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024. The company also repurchased 2.0 million shares of its common stock during the fourth quarter. "We closed 2025 having achieved another year of solid execution and meaningful pro
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial
Barclays initiated coverage of Pacira BioSciences with a rating of Equal Weight and set a new price target of $27.00
H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy
Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the co
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Total revenues of $181.1 millionNet product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera°Net loss of $4.8 million, or $0.11 per share (basic and di
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-actin
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. "Despite its prevalence, there c
-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)